Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study

Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2017

Este artículo no está incluido en ninguna revisión sistemática

Cargando información sobre las referencias
Reslizumab is a type of medicine called a monoclonal antibody that is made in the research clinic; it works by blocking a specific protein in the body called interleukin-5. The study medicine, reslizumab, is not yet approved for doctors to treat patients with EGPA. It is considered an experimental drug in this study.
Epistemonikos ID: b7202d87f75f4fe8f1581e31f860048993b42407
First added on: May 17, 2024